Zhejiang Gongdong to Acquire Trademark Plastics for Overseas Expansion
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US...
Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Shanghai Weimu Medical Raises Pre-Series A+ Funding for Clinical Development
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens...
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB...
OcuMension’s Phase I Study for Dry Eye Treatment OT-202 Concludes
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I...
Eli Lilly Reports Q4 Financials with COVID-19 Impact and Market Performers
Eli Lilly & Co. (NYSE: LLY) reported its Q4 2022 financials, revealing a 9% year-on-year...
Virpax Pharmaceuticals Seeks China Licensing Partner for Non-Opioid Pain Drug Envelta
US-based Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) has announced the engagement of advisors to help search...
Novo Nordisk Posts Strong 2022 Results; GLP-1 Therapies Drive Growth
Denmark-based diabetes giant Novo Nordisk (NYSE: NVO) has reported financial results for the fourth quarter...
Antengene Launches Phase I CLINCH Study for ATG-022 in Australia
China-based Antengene Corporation Ltd (HKG: 6996) has received approval from Australia’s Therapeutic Goods Administration (TGA)...
Henlius Begins Phase I Trial for Biosimilar HLX15 Targeting Multiple Myeloma
Shanghai Henlius Biotech (HKG: 2696) has announced the dosing of the first subject in a...
NeuShen Therapeutics Partners with UMass Chan for ALS Gene Therapy Development
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced...
F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline
The acquisition of UK-based biologics firm F-Star Therapeutics (NASDAQ: FSTX) by China’s Sino Biopharmaceutical (HKG:...
Jiangsu Hengrui’s SHR8058 Accepted for Review by China’s NMPA for Dry Eye Disease
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its market filing for the drug...
Nanjing-Based Frontier Biotechnologies Secures Full Approval for Albuvirtide in China
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary approval filing for albuvirtide, China’s first...
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts
US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high...
Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...
Ocumension Completes Enrollment for Global Phase III Study of Myopia Treatment OT-101
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced the completion of enrollment for a...
R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
Hengrui’s HER2-Targeted ADC SHR-A1811 Gains NMPA Clearance for Clinical Trial
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clearance from the National Medical Products...